In canine MM cell lines (Figure 2), cRGO1.2 (carrying NRAS p.G13R mutations) and wild-type cRGO4 exceeded the positive control A375 with respect to reductions in cell proliferation and biomass at a 1 μM concentration, with the largest reductions in cell proliferation being 95.73% and 94.82% and, in biomass, 87.76% and 84.39%. This evidence concerns the gene NRAS and Miyoshi myopathy.